Online edition of India's National Newspaper
Thursday, Nov 13, 2003

About Us
Contact Us
Business
News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts:
Classifieds | Employment | Obituary |

Business Printer Friendly Page   Send this Article to a Friend

Novartis gets EMR approval for Glivec

MUMBAI NOV. 12. Novartis India said today it has become the first pharmaceutical company in the country to be granted exclusive marketing rights (EMR) for Glivec, a drug used in treatment of cancer, by the Controller General of Patents and Trademarks of India.

"This is a positive sign to the international community that India is progressing towards meeting all its obligations under TRIPS,'' Novartis India Vice-Chairman and Managing Director, Ranjit Shahani, told newspersons here today.

Glivec is one of the oncology drugs that validate rational drug design based on an understanding of how some cancer cells work. — PTI

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts:
Classifieds | Employment | Obituary |


News Update


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |

Copyright 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu